FREE WORLDWIDE SHIPPINGContact Now
Own Factory15 Years ExperienceGMP Certified24/7 Support
WhatsApp
Back to BlogWeight Loss

Retatrutide: The New Triple Agonist for Weight Loss - What We Know

April 8, 2024By Glutathione Tationil

Retatrutide is generating significant excitement in the weight loss world as a "triple agonist" showing unprecedented results in clinical trials. Here's what we know about this promising new medication.

What is Retatrutide?

Basic Information

  • Drug Class: GLP-1/GIP/Glucagon triple receptor agonist
  • Developer: Eli Lilly
  • Status: Phase 3 clinical trials (as of 2024)
  • Trade Name: Not yet assigned
  • Route: Weekly subcutaneous injection

    • How It Differs

    MedicationReceptors Targeted SemaglutideGLP-1 only TirzepatideGLP-1 + GIP (dual) RetatrutideGLP-1 + GIP + Glucagon (triple)

    How Retatrutide Works

    Triple Mechanism

    1. GLP-1 Receptor:
  • Reduces appetite
  • Slows gastric emptying
  • Improves insulin sensitivity
  • Same as semaglutide
      • 2. GIP Receptor:
    • Enhances insulin secretion
    • Improves fat metabolism
    • Complements GLP-1 effects
    • Same addition as tirzepatide
      3. Glucagon Receptor (NEW):
    • Increases energy expenditure
    • Promotes fat burning
    • Supports liver metabolism
    • May enhance weight loss further

    Why Three May Be Better

  • More metabolic pathways targeted
  • Greater energy expenditure
  • Enhanced fat burning
  • Potentially more weight loss

    • Clinical Trial Results

    Phase 2 Trial Results (2023)

    Study Duration: 48 weeks Participants: Adults with obesity

    Weight Loss by Dose: DoseWeight Loss

    1mg8.7% 4mg17.1% 8mg22.8% 12mg24.2%

    Comparison to Other Medications

    MedicationMax Weight Loss Semaglutide 2.4mg~17% Tirzepatide 15mg~22% Retatrutide 12mg~24%

    Retatrutide shows approximately 7% more weight loss than semaglutide

    Additional Findings

  • Significant A1C reduction
  • Improved lipid profiles
  • Blood pressure improvement
  • Liver fat reduction

    • Dosing Information (From Trials)

    Studied Doses

  • 1mg weekly
  • 4mg weekly
  • 8mg weekly
  • 12mg weekly

    • Titration Schedule (Trial Protocol)

    WeekDose 1-42mg 5-84mg 9-128mg 13+Up to 12mg

    Note: Final approved dosing may differ

    Side Effects

    Common Side Effects (Similar to Other GLP-1s)

  • Nausea (most common)
  • Diarrhea
  • Vomiting
  • Constipation
  • Decreased appetite

    • Side Effect Rates (Phase 2)

    Side EffectPercentage Nausea25-45% (dose-dependent) Diarrhea15-25% Vomiting10-20% Constipation10-15%

    Glucagon-Specific Concerns

    Potential Issues Being Monitored:
  • Heart rate increases (small elevations seen)
  • Blood glucose management in diabetics
  • Long-term safety of glucagon activation

    • Current Status & Timeline

    Development Timeline

    PhaseStatus Phase 1Completed Phase 2Completed (results published) Phase 3Currently underway FDA SubmissionExpected 2025 Potential Approval2026 earliest

    Phase 3 Trials

  • TRIUMPH-1: Obesity without diabetes
  • TRIUMPH-2: Obesity with type 2 diabetes
  • TRIUMPH-3: Maintenance study
  • Results expected: 2025

    • Availability

    Current Availability

    As of 2024: NOT available for prescription
  • Still in clinical trials
  • No FDA approval yet
  • Not legally sold
  • Research only

    • Research/Compounding

    Caution: Some sources claim to sell retatrutide
  • Authenticity unverifiable
  • No quality assurance
  • Legal gray area
  • Significant risk

    • Recommendation: Wait for FDA approval

    Expected Availability Timeline

  • FDA submission: 2025 (estimated)
  • FDA approval: 2026 (if successful)
  • Market availability: 2026-2027
  • Insurance coverage: Unknown

    • Who Might Benefit Most

    Potential Ideal Candidates

  • Those who plateaued on semaglutide/tirzepatide
  • People needing maximum weight loss
  • Those with significant obesity (BMI 35+)
  • People with fatty liver disease
  • Type 2 diabetics needing aggressive treatment

    • May Not Be First Choice For

  • First-time GLP-1 users (less safety data)
  • Those with heart conditions (glucagon effects)
  • Those satisfied with current GLP-1 results
  • Budget-conscious (likely expensive)

    • Comparing the Options

    GLP-1 Evolution

    GenerationExampleApprox. Max Loss 1st GenLiraglutide8-10% 2nd GenSemaglutide15-17% DualTirzepatide20-22% TripleRetatrutide22-24%+

    Decision Framework (Future)

    Try Semaglutide First If:
  • New to GLP-1 therapy
  • Cost-sensitive
  • Prefer proven safety record
      • Consider Tirzepatide If:
    • Semaglutide insufficient
    • Need greater weight loss
    • Have type 2 diabetes
      Consider Retatrutide When Available If:
    • Other options insufficient
    • Need maximum possible loss
    • Willing to try newer medication

    What We Don't Know Yet

    Unanswered Questions

    1. Long-term safety - Only 48-week data so far 2. Optimal dosing - May change with Phase 3 3. Specific populations - Elderly, those with conditions 4. Drug interactions - Full profile unknown 5. Maintenance protocol - Long-term use unknown 6. Cost - Pricing not announced 7. Insurance coverage - Unknown

    Waiting for Phase 3 Data

  • Larger study population
  • Longer duration
  • More diverse participants
  • Better safety data
  • Real-world applicability

    • Should You Wait for Retatrutide?

    Reasons to Start Now with Available Options

  • Obesity is a health risk TODAY
  • Semaglutide/tirzepatide very effective
  • Proven safety profiles exist
  • Available now
  • Can always switch later

    • Reasons to Consider Waiting

  • Very close to goal weight
  • Current options working well
  • Prefer newest medications
  • Specific interest in glucagon effects

    • Balanced Recommendation

    Don't wait for retatrutide if you need weight loss help now. Current options are excellent. You can potentially switch to retatrutide later if needed and if it proves superior.

    Conclusion

    Retatrutide represents an exciting advancement in weight loss treatment:

      Key Points:
    • Triple agonist (GLP-1 + GIP + Glucagon)
    • Phase 2 showed up to 24% weight loss
    • Currently in Phase 3 trials
    • NOT yet available for prescription
    • Expected approval: 2026 (if successful)
      What This Means:
    • Options for weight loss keep improving
    • Those who plateau may have future options
    • Triple agonist approach looks promising
    • More data needed on long-term safety
      Recommendation:
    • If you need weight loss help NOW, use available options (semaglutide, tirzepatide)
    • Watch for Phase 3 results
    • Don't buy "retatrutide" from unverified sources
    • Discuss with your doctor when/if available

    The future of weight loss medication looks bright, with retatrutide potentially offering even more effective treatment options in the coming years.

    Tags

    retatrutidetriple agonistnew weight loss drugGLP-1 GIP glucagonweight loss 2024

    Interested in Our Products?

    Explore our range of premium glutathione, weight loss, and anti-aging products.

    Browse ProductsContact Us